KRAS-12/13 Mutation Analysis Test50+ booked in last 3 days
One of the most common somatic alterations in colon cancer and NSCLC is the presence of activating variants in the protooncogene KRAS.
Summary Price Of KRAS-12/13 Mutation Analysis Test
We are a trusted lab, offering KRAS-12/13 Mutation Analysis Test with a transparent pricing structure.
The cost of KRAS-12/13 Mutation Analysis Test in India varies as per the city in India.
The average price of KRAS-12/13 Mutation Analysis Test ranges from ₹6000 to ₹7500.
The price for the test in the following cities is:
- Chennai: ₹7,500
- Delhi: ₹6,000
- Mumbai: ₹7,500
- Pune: ₹7,500
Contact Metropolis to book an appointment online.
Frequently Asked Questions
Detecting molecular markers associated with response or resistance to specific therapy.
KRAS mutations occur in one third of human cancers and cluster in several hotspots, with codons 12 and 13 being most commonly affected.
As suggested by the doctor to detect molecular markers associated with colorectal cancer.
One of the most common somatic alterations in colon cancer and NSCLC is the presence of activating variants in the protooncogene KRAS. Current data suggest that the efficacy of EGFR-targeted therapies in colon cancer and NSCLC is confined to patients with tumors lacking KRAS mutations. An exception is the KRAS G12C variant that is targetable with variant-specific inhibitors. This test uses DNA extracted from tumor tissue to evaluate for the presence of KRAS variants. A positive result indicates the presence of an activating KRAS mutation and can be a useful marker by which patients are selected for EGFR-targeted therapy.
Ratings & Reviews (0)
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.